Vimalanand S. Prabhu

Statistics

Publications

Citations

1.4K

H-Index

Active since

2004

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Centers for Disease Control and Prevention

Eisai (United States)

Open Health Systems Laboratory

University of Washington

Vimalanand S. Prabhu is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and cost-effectiveness analysis.

ORCID

Publications per year

2004–2024

Publications

Estimating the Burden of 2009 Pandemic Influenza A (H1N1) in the United States (April 2009-April 2010)

Sundar S. Shrestha, David L. Swerdlow, Rebekah H. Borse et al. · Clinical Infectious Diseases · 2010 · 451 citations · Full text

Public Health, Infectious Diseases, Population Health Sciences +10

Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach

Kamal Desai, Swati B. Gupta, Erik R. Dubberke et al. · BMC Infectious Diseases · 2016 · 160 citations · Full text

Public Health, Infectious Diseases, Pharmacoeconomics +17

Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States

Dongmu Zhang, Vimalanand S. Prabhu, Stephen W. Marcella · Clinical Infectious Diseases · 2017 · 100 citations · Full text

Pharmacy, Infectious Diseases, Pharmacoeconomics +17

Cost-Effectiveness of Newborn Circumcision in Reducing Lifetime HIV Risk among U.S. Males

Stephanie L. Sansom, Vimalanand S. Prabhu, Angela B. Hutchinson et al. · PLoS ONE · 2010 · 81 citations · Full text

Public Health, Pharmacoeconomics, Preventive Medicine +17

Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection

Vimalanand S. Prabhu, Erik R. Dubberke, Elamin H. Elbasha et al. · Clinical Infectious Diseases · 2017 · 66 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

1–5 of 25